Hea Min Yu

Dr. Hea Min Yu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HYHea Min Yu
Hea Min Yu
HCHyo Kyun Chung
Hyo Kyun Chung
KKKoon Soon Kim
Koon Soon Kim
JLJae Min Lee
Jae Min Lee
JHJun Hwa Hong
Jun Hwa Hong
KPKang Seo Park
Kang Seo Park

1 January 2013 in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
HYHea Min Yu
Hea Min Yu
SPSoon Hyun Park
Soon Hyun Park
JLJae Min Lee
Jae Min Lee
KPKang Seo Park
Kang Seo Park
Yu HM, et al. Endocrinol Metab. 2013 Sep;28(3):226-230. http://dx.doi.org/10.3803/EnM.2013.28.3.226

1 June 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HYHea Min Yu
Hea Min Yu
HCHyo Kyun Chung
Hyo Kyun Chung
KPKang Seo Park
Kang Seo Park

19 March 2020 in Endocrinology and Metabolism
Verified
Journal Article
Open access
HYHea Min Yu
Hea Min Yu
KPKang Seo Park
Kang Seo Park
JHJun Hwa Hong
Jun Hwa Hong
KPKeun Yong Park
Keun Yong Park
JLJong Min Lee
Jong Min Lee
TOTae Kun Oh
Tae Kun Oh
Background: This study was conducted to compare glycaemic control with insulin detemir administered according to two titration algorithms (3-0-3 and 2-4-6-8) after 20 weeks of treatment in subjects with type 2 diabetes mellitus inadequately controlled on metformin. Methods: This was a 20-week, randomised, multicentre, open-labelled, treat-to-target trial. Forty-six patients were randomised in a 1:1 manner to either the 3-0-3 (G3, n=23) or 2-4-6-8 (G2, n=23) algorithm. The primary endpoint was change of haemoglobin A1c (HbA1c), and the secondary safety endpoint included hypoglycaemic events. Results: After 20 weeks, HbA1c decreased similarly in the G3 and G2 groups, with a mean change of −0.9% from baseline. The mean change in fasting plasma glucose was numerically similar in both groups. The hypoglycaemia event rate per 100-patient-years of exposure (r) in the G2 group (r=1,427) was higher than that in the G3 group (r=807). Conclusion: Both treatment groups had numerically similar HbA1c reductions. A trend towards fewer hypoglycaemia episodes after dose stabilisation was seen with the simpler G3. Clinically, this may be an important observation, as a simpler titration algorithm may support self-management and maintenance of insulin therapy.

1 January 2023 in The Korean Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
HYHea Min Yu
Hea Min Yu
JLJun Choul Lee
Jun Choul Lee

10 July 2024 in Journal of the Korean Medical Association
Verified
Journal Article
Open access
PDF file
KPKang Seo Park
Kang Seo Park
HYHea Min Yu
Hea Min Yu
Background: Diabetes mellitus is a complex group of chronic metabolic conditions. The incidence of frailty, sarcopenia, geriatric syndrome, and multiple chronic conditions is high in older patients with diabetes, who often require multiple medications for optimal glucose control and treatment of associated chronic complications. Unfortunately, polypharmacy is associated with a high risk of adverse outcomes, such as hypoglycemia, drug-drug interactions, and an increased socioeconomic burden in older adults with diabetes.Current Concepts: Elderly patients with diabetes are at a high risk for polypharmacy and consequently, a high risk of adverse drug reactions. Polypharmacy is defined as the cumulative use of five or more medications. Comprehensive management and deprescribing are the most important approaches to reduce polypharmacy. Deprescription refers to reduction in or cessation of inappropriate medications.Discussion and Conclusion: Polypharmacy continues to increase the risk of morbidity and mortality among older adults with diabetes. A comprehensive polypharmacy management and deprescription plan is warranted for significant risk reduction in elderly patients with diabetes.